RICHLAND, WA--(Marketwired - Jun 30, 2014) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the ...

RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a ...

RICHLAND, Wash.--(BUSINESS WIRE)-- IsoRay, Inc. (Amex: ISR) announced, today, it has completed an initial feasibility study, which demonstrates the ability to use its patented Cesium-131 (Cs-131) ...

RICHLAND, Wash., June 02, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk ...

RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing ...

Investors might want to bet on IsoRay (ISR), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

A pair of tweezers is used at IsoRay in Richland to pick up the titanium components used to make cesium-131 brachytherapy seeds for cancer treatment with radiation. Tri-City Herald file IsoRay Medical ...

RICHLAND, Wash.--(BUSINESS WIRE)-- IsoRay, Inc. (Amex: ISR) announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite® radiation ...

RICHLAND, Wash., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference ...

The company's growth has stalled and its costs are increasing and it doesn't look like a dramatic reverse is in sight anytime soon. Viewpoint is promising but years off from generating revenues and ...